Company: DHR
Filing Date: 2025-07-22
Form Type: 10-Q
Source: 0000313616-25-000153
Chunk: 107

Company: DANAHER CORP /DE/
Filing Date: 2025-07-22
Form: 10-Q
Item: Item 8
Chunk 107
---
 comparisons were unfavorably impacted by:

•First half of 2025 impairment charges related to a trade name in the Life Sciences segment and a facility in the Biotechnology segment - 385 basis points

•Incremental dilutive effect in 2025 of acquired businesses and the impact of a product line disposition which did not qualify as discontinued operations - 30 basis points

•The impact of product mix, changes in leverage from the Company’s operations and administrative cost structure and the impact of currency exchange rates, net of higher 2025 core sales - 15 basis points

Year-to-date 2025 vs. year-to-date 2024 operating profit margin comparisons were favorably impacted by:

•First half of 2024 acquisition-related fair value adjustment to inventory - 20 basis points

Business Segments

Sales by business segment for each of the periods indicated were as follows ($ in millions):

 Three-Month Period EndedSix-Month Period Ended June 27, 2025June 28, 2024June 27, 2025June 28, 2024Biotechnology$1,850 $1,713 $3,462 $3,237 Life Sciences1,777 1,770 3,457 3,515 Diagnostics2,309 2,260 4,758 4,787 Total$5,936 $5,743 $11,677 $11,539 

For information regarding the Company’s sales by geographical region, refer to Note 4 to the accompanying Consolidated Condensed Financial Statements.

BIOTECHNOLOGY

The Biotechnology segment includes the bioprocessing and discovery and medical businesses and offers a broad range of equipment, consumables and services that are primarily used by customers to advance and accelerate the research, development, manufacture and delivery of biological medicines.  The Company’s solutions support a broad range of biotherapeutics including monoclonal antibodies, recombinant proteins, replacement therapies such as insulin and vaccines, as well as novel cell, gene, mRNA and other nucleic acid therapies.

28

Biotechnology Selected Financial Data 

 Three-Month Period EndedSix-Month Period Ended($ in millions)June 27, 2025June 28, 2024June 27, 2025June 28, 2024Sales$1,850 $1,713 $3,462 $3,237 Operating profit531 462 972 787 Dep